Nurix Therapeutics Inc. (NRIX)
18.86
-0.18 (-0.95%)
At close: Feb 07, 2025, 3:59 PM
18.88
0.08%
After-hours Feb 07, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 18 |
| Market Cap | 1.43B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.88 |
| PE Ratio (ttm) | -6.55 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 19.65 |
| Volume | 715,717 |
| Avg. Volume (20D) | 823,363 |
| Open | 18.95 |
| Previous Close | 19.04 |
| Day's Range | 18.55 - 19.32 |
| 52-Week Range | 8.37 - 29.56 |
| Beta | undefined |
About NRIX
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malig...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 284
Stock Exchange NASDAQ
Ticker Symbol NRIX
Website https://www.nurixtx.com
Analyst Forecast
According to 17 analyst ratings, the average rating for NRIX stock is "Buy." The 12-month stock price forecast is $33, which is an increase of 74.93% from the latest price.
Buy 94.12%
Hold 5.88%
Sell 0.00%
Next Earnings Release
Nurix Therapeutics Inc. is scheduled to release its earnings on Apr 9, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+6.78%
Nurix Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
2 months ago
+6.53%
Nurix Therapeutics shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and announced a price target of $35.
